Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers October 22, 2017
Pharmacy Choice - Pharmaceutical News - Biosimilar Insulin Market Access Report 2017: Uptake of Biosimilar Insulin Varies Across EU Markets as the EMA Does Not Determine Interchangeability - Research and Markets - October 22, 2017

Pharmacy News Article

 5/18/17 - Biosimilar Insulin Market Access Report 2017: Uptake of Biosimilar Insulin Varies Across EU Markets as the EMA Does Not Determine Interchangeability - Research and Markets

DUBLIN, May 18, 2017 /PRNewswire/

Research and Markets has announced the addition of the "Biosimilar Insulin Market Access" report to their offering.

Research and Markets Logo

Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants Toujeo and Tresiba.

More aggressive payers are excluding branded insulin products in favor of the less expensive biosimilar, forcing switches in existing patient populations. As such, manufacturers of branded insulin products will need to offer deeper discounts to remain on payers' formularies and contracts.

Key Topics Covered:

1. EXECUTIVE SUMMARY

2. U.S

  • Insights and strategic recommendations
  • U.S payers are adopting a wait-and-see approach for biosimilar Basaglar
  • Bibliography

3. FIVE MAJOR EU MARKETS

  • Insights and strategic recommendations
  • Uptake of biosimilar insulin varies across EU markets as the EMA does not determine interchangeability
  • Physicians and payers have varying views on the interchangeability of biosimilar insulins, but see large opportunities to reduce costs
  • Payers use biosimilars to pressure originators on pricing
  • Pharmacies continue to procure both biosimilars and originators; dynamic pricing environment observed
  • Patient switching requires significant discounts of at least 30%
  • Given attractive discounts, payers will use a variety of market access tools to drive Basaglar's uptake
  • Bibliography

4. METHODOLOGY

  • Primary research

For more information about this report visit http://www.researchandmarkets.com/research/qtj6df/biosimilar

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716



To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biosimilar-insulin-market-access-report-2017-uptake-of-biosimilar-insulin-varies-across-eu-markets-as-the-ema-does-not-determine-interchangeability-research-and-markets-300459942.html

SOURCE Research and Markets




Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Oct 23: Vitamin D Primer for Pharmacy Professionals
Oct 24: Metabolic Syndrome: The Heart of Any Wellness Practice
Oct 25: Dispensing Controlled Substances in Today’s Pharmacy
Oct 26: Management of Schizophrenia & Acute Agitation
Oct 27: Influenza 2017-2018: An Update on Prevention and Treatment
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415